A four week randomised control trial of adjunctive medroxyprogesterone and
tamoxifen in women with mania.
Author(s): Kulkarni J(1), Berk M(2), Wang W(3), Mu L(3), Scarr E(4), Van Rheenen TE(3),
Worsley R(5), Gurvich C(3), Gavrilidis E(3), de Castella A(3), Fitzgerald P(3),
Davis SR(6).
Affiliation(s): Author information:
(1)Monash Alfred Psychiatry Research Centre, Central Clinical School, Monash
University and the Alfred Hospital, Melbourne, Victoria 3004, Australia.
Electronic address: jayashri.kulkarni@monash.edu. (2)IMPACT Strategic Research
Centre, School of Medicine, Deakin University, Barwon Health, Ryrie Street,
Geelong, Victoria 3220, Australia. (3)Monash Alfred Psychiatry Research Centre,
Central Clinical School, Monash University and the Alfred Hospital, Melbourne,
Victoria 3004, Australia. (4)The Florey Institute of Neuroscience and Mental
Health Victoria, Parkville, Victoria 3052, Australia. (5)Monash Alfred Psychiatry
Research Centre, Central Clinical School, Monash University and the Alfred
Hospital, Melbourne, Victoria 3004, Australia; Women's Health Research Program,
School of Public Health and Preventive Medicine, Monash University and Alfred
Hospital, Victoria 3004, Australia. (6)Women's Health Research Program, School of
Public Health and Preventive Medicine, Monash University and Alfred Hospital,
Victoria 3004, Australia.
Publication date & source: 2014, Psychoneuroendocrinology. , 43:52-61
Emerging research has suggested that hormone treatments such as selective
oestrogen receptor modulators (SERMs) or progestins may be useful in the
treatment of mania. The current pilot study compared the use of the SERM
tamoxifen and the progestin medroxyprogesterone acetate (MPA), as an adjunct to
mood stabiliser medications, for the treatment of mania symptoms in 51 women in a
28-day double blind, placebo controlled study. The primary outcome was the change
between baseline and day 28 mania scores as measured by the Clinician
Administered Rating Scale for Mania (CARS-M). Adjunctive MPA treatment provided
greater and more rapid improvement in mania symptoms compared with adjunctive
placebo and tamoxifen treatment. Adjunctive therapy with MPA may be a potentially
useful new treatment for persistent mania, leading to a greater and more rapid
resolution of symptoms compared with mood stabiliser treatment alone.
|